Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Alnylam Pharmaceuticals Inc

Healthcare US ALNY

292.58USD
6.46(2.26%)

Last update at 2026-06-03T20:19:00Z

Day Range

283.10293.16
LowHigh

52 Week Range

238.62495.55
LowHigh

Fundamentals

  • Previous Close 286.12
  • Market Cap41153.17M
  • Volume986322
  • P/E Ratio131.81
  • Dividend Yield-%
  • EBITDA557.24M
  • Revenue TTM3713.94M
  • Revenue Per Share TTM28.35
  • Gross Profit TTM 3032.07M
  • Diluted EPS TTM2.34

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 323.15M -377.37500M -433.51700M -1126.99300M -852.14400M
Minority interest - - - - -
Net income 313.75M -278.15700M -440.24200M -1131.15600M -852.82400M
Selling general administrative 1210.71M 975.53M 795.65M 770.66M 620.64M
Selling and marketing expenses - - - - -
Gross profit 3036.77M 1924.87M 1517.89M 868.60M 704.14M
Reconciled depreciation 55.66M 56.67M 97.03M 85.55M 89.69M
Ebit 501.58M -235.51700M -312.29600M -785.07200M -708.65200M
Ebitda 557.24M -178.84700M -258.24200M -894.43900M -709.12300M
Depreciation and amortization 55.66M 56.67M 54.05M -109.36700M -0.47100M
Non operating income net other - - - -185.95300M -0.47100M
Operating income 501.58M -176.88500M -282.17500M -785.07200M -708.65200M
Other operating expenses 3212.36M 2425.13M 2110.47M 1822.49M 1552.94M
Interest expense 252.63M 141.86M 121.22M 155.97M 143.02M
Tax provision 9.40M -99.21800M 6.72M 4.16M 0.68M
Interest income 111.47M 121.99M 95.56M 24.81M 1.58M
Net interest income -141.15700M -19.86600M -25.66000M -131.16000M -141.44200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 9.40M -99.21800M 6.72M 4.16M 0.68M
Total revenue 3713.94M 2248.24M 1828.29M 1037.42M 844.29M
Total operating expenses 2535.19M 2101.76M 1800.06M 1653.67M 1412.80M
Cost of revenue 677.17M 323.37M 310.41M 168.82M 140.14M
Total other income expense net -178.42600M -200.49000M -151.34200M -341.92100M -143.49200M
Discontinued operations - - - - -
Net income from continuing ops 313.75M -278.15700M -440.24200M -1131.15600M -852.82400M
Net income applicable to common shares - - - -1131.15600M -852.82400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 4966.33M 4239.98M 3829.88M 3546.36M 3643.30M
Intangible assets 593.73M - 697.78M 264.56M -
Earning assets - - - - -
Other current assets 281.89M 116.96M 126.38M 132.92M 111.94M
Total liab 4177.15M 4172.90M 4050.52M 3704.58M 3055.10M
Total stockholder equity 789.18M 67.09M -220.64400M -158.22300M 588.20M
Deferred long term liab - - - - -
Other current liab 1300.27M 887.47M 713.01M 585.75M 494.14M
Common stock 1.32M 1.29M 1.26M 1.24M 1.20M
Capital stock 1.32M 1.29M 1.26M 1.24M 1.20M
Retained earnings -6702.52400M -7287.74800M -7009.59100M -6569.34900M -5438.19300M
Other liab - - - 406.37M 1402.35M
Good will - - - - -
Other assets - 61.83M - 115.48M 101.09M
Cash 1657.25M 966.43M 812.69M 866.39M 819.98M
Cash and equivalents - - - - -
Total current liabilities 1466.35M 1186.27M 967.79M 767.91M 1191.30M
Current deferred revenue 4.84M 55.48M 102.75M 42.10M 301.84M
Net debt -378.86100M 1776.99M 1869.94M 453.85M 177.62M
Short term debt 45.52M 154.90M 96.50M 41.97M 321.89M
Short long term debt - - - - -
Short long term debt total 1278.39M 2743.42M 2682.63M 1320.25M 997.59M
Other stockholder equity 7510.47M 7388.06M 6811.06M 6454.54M 6058.45M
Property plant equipment - - - 523.49M 501.96M
Total current assets 4050.66M 3295.28M 2982.70M 2692.25M 2868.78M
Long term investments - - - - -
Net tangible assets - - - -158.22300M 588.20M
Short term investments 1251.23M 1728.08M 1626.69M 1326.01M 1615.59M
Net receivables 777.57M 405.31M 327.79M 237.96M 198.57M
Long term debt 1007.78M 1024.62M 1020.78M 1016.94M 675.70M
Inventory 82.72M 78.51M 89.15M 128.96M 122.70M
Accounts payable 115.72M 88.42M 55.52M 98.09M 73.43M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -20.09700M -34.51800M -23.37500M -44.65400M -33.25900M
Additional paid in capital - - - - -
Common stock total equity - - - 1.24M 1.20M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -6569.34900M -5438.19300M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 81.63M 133.90M -3526.75400M 115.48M 40.89M
Deferred long term asset charges - - - - -
Non current assets total 915.67M 944.70M 847.18M 854.11M 774.52M
Capital lease obligations 270.61M 271.43M 284.61M 303.31M 321.89M
Long term debt total - - - 1016.94M 675.70M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 497.18M -116.84000M -235.60500M 169.35M -192.56400M
Change to liabilities - - - 191.77M 88.24M
Total cashflows from investing activities 436.33M -116.84000M -336.35000M 169.35M -273.30000M
Net borrowings -544.53200M 0.00000M 0.00000M 254.00M 500.00M
Total cash from financing activities -305.19000M 294.16M 172.13M 425.75M 1247.12M
Change to operating activities - - - -81.67800M -72.44500M
Net income 313.75M -278.15700M -440.24200M -1131.15600M -852.82400M
Change in cash 690.15M 153.77M -53.67200M 46.40M 323.11M
Begin period cash flow 968.65M 814.88M 868.56M 822.15M 499.05M
End period cash flow 1658.81M 968.65M 814.88M 868.56M 822.15M
Total cash from operating activities 524.08M -8.31200M 104.16M -541.27400M -641.69300M
Issuance of capital stock - - - 0.00000M 0.00000M
Depreciation 55.66M 56.67M 97.03M 85.55M 89.69M
Other cashflows from investing activities 57.62M 57.76M -4.43800M -13.19400M -4.36400M
Dividends paid - - - - -
Change to inventory 8.47M 13.59M 18.37M -34.13600M -26.41500M
Change to account receivables -359.96300M -86.55000M -87.93900M -45.59700M -101.79900M
Sale purchase of stock - - - 259.36M 246.27M
Other cashflows from financing activities -8.27200M -8.79200M 24.67M 928.50M 1247.12M
Change to netincome - - - 307.71M 223.39M
Capital expenditures 58.70M 34.28M 62.21M 72.06M 76.37M
Change receivables - - - -45.59700M -101.79900M
Cash flows other operating - - - 125.66M -19.85500M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 53.83M 332.12M
Change in working capital -444.78200M -214.08400M 10.76M -35.55300M -162.82300M
Stock based compensation 348.24M 272.08M 221.68M 230.65M 165.72M
Other non cash items 253.42M 261.94M 214.93M 309.24M 174.24M
Free cash flow 465.38M -42.58900M 41.95M -613.33300M -718.06500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ALNY
Alnylam Pharmaceuticals Inc		 6.46 2.26% 292.58 131.81 34.97 11.08 52.15 10.64 62.59
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals Inc

675 West Kendall Street, Cambridge, MA, United States, 02142

Key Executives

Name Title Year Born
Mr. Michael W. Bonney B.A. Exec. Chairman 1958
Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB CEO & Director 1963
Dr. Akshay K. Vaishnaw M.D., Ph.D. Pres 1963
Mr. Jeffrey V. Poulton M.B.A. CFO & Exec. VP 1968
Mr. Tolga Tanguler M.B.A. Exec. VP & Chief Commercial Officer NA
Dr. Alfred W. Boyle Ph.D. Chief Technical Operations & Quality Officer NA
Dr. Kevin Joseph Fitzgerald Ph.D. Sr. VP, Head of Research & Chief Scientific Officer 1968
Ms. Christine Regan Lindenboom Sr. VP of Investor Relations & Corp. Communications NA
Ms. Indrani M. Lall Franchini J.D. Exec. VP, Chief Legal Officer & Sec. 1972
Mr. Piyush Sharma J.D. Chief Ethics & Compliance Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions